Antioxidant effect of atorvastatin is independent of PON1 gene T(–107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients
- 31 March 2005
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 21 (5), 777-784
- https://doi.org/10.1185/030079905x45170
Abstract
Serum paraoxonase (PON1), a high density lipoprotein (HDL)-bound antioxidant enzyme, plays a role in atherosclerosis. An increase in PON1 activity has been reported following statin treatment. In the present study the following factors were evaluated: the influence of PON1 gene Q192R, L55M and T(-107)C polymorphisms on the response of LDL oxidisability and PON1 activity to atorvastatin treatment. 205 Sicilian subjects with primary hypercholesterolaemia (HCh) and 69 healthy subjects as controls were concurrently enrolled. Hypercholesterolaemic patients were randomly divided into two groups: an atorvastatin group (10 mg/day atorvastatin) and a placebo group. Lipid profile, markers of LDL resistance to in vitro oxidation (lag-phase, oxidation rate and thiobarbituric acid-reactive substances), vitamin E content in LDL, PON1 activity and genotypes in both HCh and control subjects were determined at baseline. The same parameters were measured again after 3 weeks of treatment in both the atorvastatin and placebo groups. HCh subjects showed significantly lower LDL resistance to oxidation, vitamin E content and PON1 activity levels than controls. A strong association was found among PON1 T(-107)C genotypes, LDL susceptibility to oxidation, vitamin E content and PON1 activity. After treatment, the atorvastatin group displayed a significant decrease in total cholesterol, LDL-cholesterol levels, and LDL susceptibility to oxidation, and an increase in vitamin E content and PON1 activity, compared with baseline values. Unlike PON1 activity levels, no difference among PON1 gene polymorphisms and reduction in markers of LDL oxidisability was observed. These results show, for the first time, that atorvastatin is able to improve the resistance to LDL oxidation independently of PON1 gene polymorphism.Keywords
This publication has 19 references indexed in Scilit:
- Decreased Macrophage Paraoxonase 2 Expression in Patients With Hypercholesterolemia Is the Result of Their Increased Cellular Cholesterol Content: Effect of Atorvastatin TherapyArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Simvastatin Modulates Expression of the PON1 Gene and Increases Serum ParaoxonaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian populationEuropean Journal of Clinical Investigation, 2002
- The paraoxonase Leu–Met54 and Gln–Arg191 gene polymorphisms are not associated with the risk of coronary heart diseaseAtherosclerosis, 2000
- Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study Commentary: Causality---the Achilles' heel of observational studies Commentary: How high density lipoprotein protects against heart diseaseBMJ, 1999
- Simvastatin decreases aldehyde production derived from lipoprotein oxidationThe American Journal of Cardiology, 1999
- DNA Polymorphisms in Two Paraoxonase Genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart DiseaseAmerican Journal of Human Genetics, 1998
- Genetic Polymorphism of Paraoxonase and the Risk of Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetesThe Lancet, 1995
- Improved Measurement of Low-Density-Lipoprotein Susceptibility to Copper-Induced Oxidation: Application of a Short Procedure for Isolating Low-Density LipoproteinClinical Chemistry, 1992